Department of Neurobiology, Neuroscience Institute, Morehouse School of Medicine, Atlanta, GA 30310, USA.
Brain Res. 2010 Nov 4;1359:247-55. doi: 10.1016/j.brainres.2010.08.075. Epub 2010 Sep 21.
Fibrates are activators of peroxisome proliferator-activated receptor (PPAR) α. Pretreatment with fibrates has been shown to protect brain against ischemia in mice. We hypothesized that fibrates elevate superoxide dismutase (SOD) levels in the brain microvessels (BMVs). BMVs were isolated from male C57BL/6 and PPARα null mice that had been treated with fenofibrate or gemfibrozil for 7 days. To examine the effect of discontinuation of fenofibrate, another animal group treated with fenofibrate was examined on post-discontinuation day 3 (D-3). To examine whether SOD elevations attenuate oxidative stress in the ischemic brain, separate animals treated with fenofibrate for 7 days were subjected to 60 minutes of focal ischemia on post-discontinuation day 0 (D-0) or D-3. Fenofibrate (30 mg/kg) increased mRNA levels of all three isoforms of SOD and activity level in BMV on D-0, but these effects were not detected on D-3. The elevations were not detected in PPARα null mice. SOD levels were also elevated by gemfibrozil (30 mg/kg). Fenofibrate significantly reduced superoxide production and protein oxidation in the ischemic brain at 30 minutes after reperfusion. Fenofibrate reduced infarct size measured at 24 hours after reperfusion on D-0; however, the infarct reduction was not seen when ischemia was induced on D-3. These findings suggest that fibrates elevate SOD in BMV through PPARα, which contributes to the infarct reduction, at least in part. Further studies are needed to establish the link between the SOD elevations and the brain protection by fibrates against ischemia.
贝特类药物是过氧化物酶体增殖物激活受体 (PPAR)α 的激活剂。研究表明,贝特类药物预处理可保护小鼠大脑免受缺血损伤。我们假设贝特类药物可提高脑微血管 (BMV) 中的超氧化物歧化酶 (SOD) 水平。从接受非诺贝特或吉非贝齐治疗 7 天的雄性 C57BL/6 和 PPARα 基因敲除小鼠中分离出 BMV。为了研究非诺贝特停药的影响,检查了另一组接受非诺贝特治疗的动物在停药后第 3 天 (D-3) 的情况。为了研究 SOD 升高是否减轻缺血性脑内的氧化应激,将接受非诺贝特治疗 7 天的单独动物在停药后第 0 天 (D-0) 或第 3 天 (D-3) 进行 60 分钟的局灶性缺血。非诺贝特 (30mg/kg) 增加了 D-0 时 BMV 中所有三种 SOD 同工酶的 mRNA 水平和活性水平,但在 D-3 时未检测到这些效应。在 PPARα 基因敲除小鼠中未检测到这些增加。吉非贝齐 (30mg/kg) 也可升高 SOD 水平。非诺贝特在再灌注 30 分钟后可显著减少缺血性脑内的超氧阴离子生成和蛋白氧化。非诺贝特在 D-0 时降低了再灌注 24 小时后的梗死面积;然而,在 D-3 时诱导缺血时未观察到梗死面积减少。这些发现表明,贝特类药物通过 PPARα 增加 BMV 中的 SOD,这有助于至少部分减少梗死,至少部分是通过 PPARα 增加 SOD。需要进一步的研究来建立 SOD 升高与贝特类药物对缺血性脑保护之间的联系。